About Huntington’s Disease Therapeutics HD is an inherited condition that leads to destruction of nerve cells or neurons. The damage to nerve cells usually causes change in personality, mood swings, irritability and altered behavior. The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics. Technavio’s analysts forecast the global huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global huntington’s disease therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off label drugs. The market is divided into the following segments based on geography: • Americas • APAC • EMEA Technavio's report, Global Huntington’s Disease Therapeutics Market 2017-2021, has been prepared based on an... Research Beam Model: Research Beam Product ID: 1908014 3500 USD New
Global Huntingtons Disease Therapeutics Market 2017-2021
 
 

Global Huntingtons Disease Therapeutics Market 2017-2021

  • Category : Healthcare
  • Published On : August   2017
  • Pages : 86
  • Publisher : Technavio
 
 
 
About Huntington’s Disease Therapeutics

HD is an inherited condition that leads to destruction of nerve cells or neurons. The damage to nerve cells usually causes change in personality, mood swings, irritability and altered behavior. The global HD therapeutics market was witnessing a high unmet demand for disease modifying drug, in the presence of only one approved therapy, Xenazine, and the off-label use of various different therapeutics. The introduction of AUSTEDO in the market will have a significant impact on the market growth, thereby changing the market dynamics.

Technavio’s analysts forecast the global huntington’s disease therapeutics market to grow at a CAGR of 14.75% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global huntington’s disease therapeutics market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off label drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Huntington’s Disease Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• F. Hoffmann-La Roche
• H. Lundbeck
• Prana Biotechnology
• Teva Pharmaceutical Industries
Other prominent vendors
• Intellect Neurosciences
• Horizon Pharma
• Sangamo Therapeutics
• Vertex Pharmaceuticals

Market driver
• Early onset of disease symptoms, increases the demand for HD therapeutics
• For a full, detailed list, view our report

Market challenge
• Increase in alternative programs for management of mental disorders
• For a full, detailed list, view our report

Market trend
• Advances in biomedical sciences
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: HD: An introduction
PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Pipeline
PART 08: Market segmentation by drug-class
• Market scenario by drug-class
• Antidopaminergics
• Anticonvulsants
• Antipsychotics
• Antidepressants
• Others
PART 09: Geographical segmentation
• Market segmentation by geography
• HD therapeutics market in Americas
• HD therapeutics market in EMEA
• HD therapeutics market in APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Advances in biomedical sciences
• Focus on regenerative therapies for mental disorders
• Rising public interest toward mental health
PART 13: Vendor landscape
• Competitive scenario
PART 14: Key vendor analysis
• F. Hoffmann-La Roche
• H. Lundbeck
• Prana Biotechnology
• Teva Pharmaceutical Industries
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
List of Exhibits?
Exhibit 01: Parts of brain affected by HD
Exhibit 02: Key facts about HD
Exhibit 03: Prevalence and incidence of HD
Exhibit 04: Neurotransmitter involved in pathogenesis of HD
Exhibit 05: Market snapshot
Exhibit 06: Global HD therapeutics market 2016-2021 ($ millions)
Exhibit 07: Opportunity analysis of global HD therapeutics market
Exhibit 08: Five forces analysis
Exhibit 09: Pipeline landscape based on number of molecules 2016
Exhibit 10: HD: Key clinical trials
Exhibit 11: Segmentation of global HD therapeutics market by drug-class
Exhibit 12: Global HD therapeutics market share by drug-class
Exhibit 13: Antidopaminergics used in HD
Exhibit 14: Uses and side-effects of antidopaminergics
Exhibit 15: Global HD therapeutics market by antidopaminergics 2016-2021 ($ millions)
Exhibit 16: Pharmacologic approach for the treatment of chorea
Exhibit 17: Anticonvulsants used in HD
Exhibit 18: Uses and side-effects of anticonvulsants
Exhibit 19: Global HD therapeutics market by anticonvulsants 2016-2021 ($ millions)
Exhibit 20: Antipsychotics used in HD
Exhibit 21: Uses and side-effects of antipsychotics
Exhibit 22: Global HD therapeutics market by antipsychotics 2016-2021 ($ millions)
Exhibit 23: Symptoms of depression associated with HD
Exhibit 24: Global HD therapeutics market by antidepressants 2016-2021 ($ millions)
Exhibit 25: Symptoms of mania associated with HD
Exhibit 26: Global HD therapeutics market share by geography 2016 and 2021
Exhibit 27: Global HD therapeutics market revenue by geography 2016-2021
Exhibit 28: Global HD therapeutics market share by geography 2016-2021
Exhibit 29: HD therapeutics market scenario in different geographies
Exhibit 30: Market scenario in Americas
Exhibit 31: HD therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 32: Market scenario in EMEA
Exhibit 33: HD therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario in APAC
Exhibit 35: HD therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 36: Planned clinical trials of iPS cell-based therapies
Exhibit 37: Competitive structure analysis of global HD therapeutics market 2016
Exhibit 38: F. Hoffmann-La Roche: Key highlights
Exhibit 39: F. Hoffmann-La Roche: Strength assessment
Exhibit 40: F. Hoffmann-La Roche: Strategy assessment
Exhibit 41: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 42: H. Lundbeck: Key highlights
Exhibit 43: H. Lundbeck: Strength assessment
Exhibit 44: H. Lundbeck: Strategy assessment
Exhibit 45: H. Lundbeck: Opportunity assessment
Exhibit 46: Prana Biotechnology: Key highlights
Exhibit 47: Prana Biotechnology: Strength assessment
Exhibit 48: Prana Biotechnology: Strategy assessment
Exhibit 49: Prana Biotechnology: Opportunity assessment
Exhibit 50: Teva Pharmaceuticals: Key highlights
Exhibit 51: Teva Pharmaceuticals: Strength assessment
Exhibit 52: Teva Pharmaceuticals: Strategy assessment
Exhibit 53: Teva Pharmaceuticals: Opportunity assessment

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 

Related Reports

REQUEST SAMPLE    ASK FOR DISCOUNT